Q1 Earnings Estimate for uniQure Issued By Leerink Partnrs

Key Points

• Leerink Partners forecasts uniQure N.V. to report a Q1 2026 EPS of ($1.16), while the full-year estimate stands at ($3.75) per share.
• Analyst ratings for uniQure show a consensus of "Buy" with a target price averaging at $37.45.
• Insider activity revealed recent share sales with directors decreasing their holdings, as well as a significant increase in institutional ownership to 78.83% of the company.

uniQure N.V. (NASDAQ:QURE - Free Report) - Leerink Partnrs issued their Q1 2026 earnings per share estimates for uniQure in a research note issued on Monday, August 18th. Leerink Partnrs analyst J. Schwartz expects that the biotechnology company will post earnings of ($1.16) per share for the quarter. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for uniQure's Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at $1.10 EPS, FY2026 earnings at ($2.28) EPS and FY2027 earnings at ($1.55) EPS.

A number of other analysts have also recently issued reports on the company. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price objective for the company in a research report on Thursday, August 14th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research report on Wednesday, July 30th. Guggenheim restated a "buy" rating and set a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Finally, HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $37.45.

uniQure Stock Down 1.0%

QURE traded down $0.15 during trading on Thursday, reaching $15.55. 410,274 shares of the stock traded hands, compared to its average volume of 1,368,405. The stock has a market cap of $853.18 million, a price-to-earnings ratio of -3.97 and a beta of 0.11. uniQure has a fifty-two week low of $4.45 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock's 50-day simple moving average is $14.56 and its two-hundred day simple moving average is $13.60.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.

Insider Buying and Selling at uniQure

In related news, insider Jeannette Potts sold 4,670 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider owned 115,073 shares of the company's stock, valued at approximately $1,742,205.22. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Gut sold 3,336 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $48,205.20. Following the transaction, the director directly owned 56,879 shares of the company's stock, valued at $821,901.55. This represents a 5.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,144 shares of company stock worth $322,426 in the last ninety days. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently made changes to their positions in QURE. Main Management ETF Advisors LLC raised its position in shares of uniQure by 1.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company's stock valued at $786,000 after acquiring an additional 912 shares during the last quarter. Tudor Investment Corp ET AL raised its position in shares of uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 1,371 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Northern Trust Corp raised its position in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after acquiring an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock valued at $1,253,000 after acquiring an additional 3,996 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.